A phase IIa study showed that patients with ER+ breast cancer who had progressed on aromatase inhibitors could benefit from the pan‐FGFR inhibitor AZD4547, regardless of their FGFR1 amplification status or expression levels.51 This evidence concerns the gene FGFR1 and breast carcinoma.